Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

Inclusion Criteria: 1. Signed and dated written Informed Consent (if unconscious due to a critical condition, the decision is made by a Council consisting of 3 physicians) 2. Male and female patients aged 18-70 3. Critical illness ((shock (including traumatic, hypovolemic), major trauma, acute massive blood loss, acute complicated surgical diseases of the abdominal organs) accompanied by metabolic acidosis, defined as serum bicarbonate \<22mmol/L 4. pH of arterial blood 7.20-7.35, inclusive 5. Planned volume of infusion \>= 1500 ml per day 6. Interval between admission to the ICU and randomization \<24 hours Exclusion Criteria: 1. Pregnant and lactating women 2. Known hypersensitivity to any component of the study drug / placebo 3. Chronic kidney disease stage C5 (end-stage renal failure) 4. Acute hepatic failure (ALT \> 15 upper normal limits) or liver cirrhosis 5. Traumatic brain injury accompanied by cerebral edema 6. Previously diagnosed mental illness 7. Any chronic disease in the terminal stage with a life expectancy of \< 3 months 8. HIV infection 9. Clinically significant cardiovascular disease (unstable angina pectoris or angina pectoris of functional class III or higher; chronic heart failure III - IV class according to NYHA; acute myocardial infarction within 6 months before screening) 10. Extremely low or extremely high body fat 11. Infusion sodium bicarbonate, sodium bicarbonate, trometamol, Sterofundin, Quintasol, Ringer's lactate (Hartmann's solution) within 6 hours before screening 12. Acute respiratory acidosis 13. Poisoning with chemical compounds causing metabolic acidosis 14. Alcohol in saliva at screening \>= 0.5 pro mille 15. Previously diagnosed chronic obstructive pulmonary disease